In April 2018 the technology validation was successfully completed indicating a great potential of Glycanostics innovative products for prostate cancer (PCa) diagnostics. The test showed 95+% accuracy (100% assay sensitivity and 94% assay specificity), which is much more accurate than the most commonly used PSA test (83% assay sensitivity and 39% assay specificity) and PCA3 benchmarks. That literally means that Glycanostics PCa DX kit can correctly identify 100% PCa patients and 94% of healthy men which makes a real revolution in prostate cancer diagnostics!
Using this innovative approach only 6% of healthy men will be sent to unnecessary biopsies, while with standard PSA this number is over 60%. In such a way Glycanostics PCa DX kit will help to avoid thousands of unnecessary biopsies which bring patients emotional distress, significant financial expenses and possible health complications.
At the same time, Glycanostics innovative product can be also used as a second opinion test after the biopsy was performed. In fact, only 26% of biopsies confirm PCa, other 74% require further surveillance and/or re-biopsy. Another biopsy problem is that 20- 30% of PCa patients are diagnosed false-negative. Thus using Glycanostics PCa DX kit as a second opinion test after performed biopsy can decrease mortality, increase the efficiency of treatment and avoid unnecessary sufferings as well as financial loads for patients.
“Our next steps are optimization of the assay performance and pre-clinical and retrospective validation study with 450 serum samples. That will speed up the process of commercialization of the clinical test and bring it to the market.”
comments professor Jan Tkac, co-founder and executive manager of Glycanostics Ltd.
Glycanoctics innovations are again supported and highly ranked by leading industry experts. This time the company won the European Research Council (ERC) Proof of Concept Grant.
Glycanostics is an innovative start-up company established in 2017 to bring its revolutionary cancer diagnostics products to the US and EU markets.